253 related articles for article (PubMed ID: 24184213)
1. Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
Juvale K; Gallus J; Wiese M
Bioorg Med Chem; 2013 Dec; 21(24):7858-73. PubMed ID: 24184213
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
Krapf MK; Gallus J; Wiese M
Eur J Med Chem; 2017 Oct; 139():587-611. PubMed ID: 28841513
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
Juvale K; Stefan K; Wiese M
Eur J Med Chem; 2013 Sep; 67():115-26. PubMed ID: 23851114
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).
Krapf MK; Wiese M
J Med Chem; 2016 Jun; 59(11):5449-61. PubMed ID: 27148793
[TBL] [Abstract][Full Text] [Related]
5. 4-Substituted-2-phenylquinazolines as inhibitors of BCRP.
Juvale K; Wiese M
Bioorg Med Chem Lett; 2012 Nov; 22(21):6766-9. PubMed ID: 23017888
[TBL] [Abstract][Full Text] [Related]
6. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
7. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
Juvale K; Pape VF; Wiese M
Bioorg Med Chem; 2012 Jan; 20(1):346-55. PubMed ID: 22112540
[TBL] [Abstract][Full Text] [Related]
8. Design of inhibitors of BCRP/ABCG2.
Juvale K; Wiese M
Future Med Chem; 2015 Aug; 7(12):1521-7. PubMed ID: 26293476
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
10. The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
Kraege S; Stefan K; Juvale K; Ross T; Willmes T; Wiese M
Eur J Med Chem; 2016 Jul; 117():212-29. PubMed ID: 27100033
[TBL] [Abstract][Full Text] [Related]
11. Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e]azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.
Gu X; Tang X; Zhao Q; Peng H; Peng S; Zhang Y
Bioorg Med Chem Lett; 2014 Aug; 24(15):3419-21. PubMed ID: 24928398
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.
Krapf MK; Gallus J; Spindler A; Wiese M
Eur J Med Chem; 2019 Jan; 161():506-525. PubMed ID: 30390439
[TBL] [Abstract][Full Text] [Related]
13. Scaffold identification of a new class of potent and selective BCRP inhibitors.
Marighetti F; Steggemann K; Karbaum M; Wiese M
ChemMedChem; 2015 Apr; 10(4):742-51. PubMed ID: 25735648
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
16. 4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2).
Krapf MK; Gallus J; Wiese M
J Med Chem; 2017 May; 60(10):4474-4495. PubMed ID: 28471656
[TBL] [Abstract][Full Text] [Related]
17. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
[TBL] [Abstract][Full Text] [Related]
18. Bifendate-chalcone hybrids: a new class of potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.
Gu X; Ren Z; Peng H; Peng S; Zhang Y
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):318-22. PubMed ID: 25446092
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
Pick A; Müller H; Mayer R; Haenisch B; Pajeva IK; Weigt M; Bönisch H; Müller CE; Wiese M
Bioorg Med Chem; 2011 Mar; 19(6):2090-102. PubMed ID: 21354800
[TBL] [Abstract][Full Text] [Related]
20. 2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2.
Krapf MK; Gallus J; Namasivayam V; Wiese M
J Med Chem; 2018 Sep; 61(17):7952-7976. PubMed ID: 30075623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
